01 — Cancer Foundations: Clonal Evolution, Oncogenes, and Tumor Suppressors

Core Explanation

Cancer is fundamentally a genetic disease of somatic cells — it arises from the stepwise accumulation of mutations that confer a selective growth advantage on a single cell and its descendants. Unlike inherited genetic diseases, which are present in every cell from conception, cancer-associated mutations are acquired in somatic tissues over a lifetime. The process is best understood through the lens of clonal evolution.

The Clonal Evolution Model

In 1976, Peter Nowell proposed that tumor progression mirrors Darwinian evolution operating on a population of cells within an organism:

1. A single cell acquires a mutation that provides a slight proliferative or survival advantage.
2. That cell divides, producing a clonal population bearing the founding mutation.
3. Within this expanding clone, random mutations continue to arise. Most are neutral or deleterious, but occasionally one confers an additional fitness advantage.
4. The subclone carrying two advantageous mutations outcompetes its neighbors — a clonal sweep.
5. Over many generations, sequential rounds of mutation, selection, and expansion produce progressively more aggressive subclones.

The end result is tumor heterogeneity: a single patient's tumor contains multiple genetically distinct subclones that share a common ancestor but have diverged through branching evolution. This heterogeneity is a major barrier to therapy — a drug that eliminates the dominant clone may leave resistant subclones that repopulate the tumor.

Benign vs. Malignant Tumors

The distinction between benign and malignant is not a binary switch but a spectrum. Some benign lesions (e.g., colonic adenomas) are premalignant — they harbor early mutations and have a statistical risk of progressing to carcinoma if additional mutations accumulate.

Metastasis: The Multi-Step Cascade

Metastasis is an inefficient process. Of the millions of cells that a primary tumor may shed into the circulation daily, fewer than 0.01% successfully form clinically detectable metastases. The cascade involves:

1. Local invasion: Tumor cells breach the basement membrane and invade the surrounding stroma.
2. Intravasation: Entry into blood or lymphatic vessels.
3. Survival in circulation: Resistance to anoikis (detachment-induced apoptosis) and shear stress.
4. Arrest and extravasation: Exit from vessels at a distant organ.
5. Colonization: Proliferation in the foreign microenvironment to form a clinically relevant metastasis.

Oncogenes: Gain-of-Function Drivers

Oncogenes are mutated or overexpressed versions of normal cellular genes (proto-oncogenes) that normally promote cell growth, survival, or proliferation. Oncogenic mutations are genetically dominant — a single mutant allele is sufficient to drive the phenotype, even in the presence of a normal allele.

Activation Mechanisms

• Point mutations: A single amino acid change can lock the protein in a constitutively active state.
• Gene amplification: Multiple copies of the gene increase protein expression (e.g., HER2/ERBB2 amplification).
• Chromosomal translocations: Fusion to a highly active promoter or to another gene creates a hyperactive protein (e.g., BCR-ABL in chronic myeloid leukemia).
• Viral insertion: Retroviral promoter insertion upstream of a proto-oncogene (rare in human cancer, historically important in discovery).

Key Oncogenes

Tumor Suppressor Genes: Loss-of-Function Guardians

Tumor suppressor genes normally restrain proliferation, promote DNA repair, or trigger apoptosis. They are genetically recessive at the cellular level — both alleles must be inactivated for the phenotype to manifest. This "two-hit" mechanism was first articulated by Alfred Knudson in 1971 for retinoblastoma.

The first hit is often a point mutation or small deletion; the second is frequently loss of heterozygosity (LOH) — deletion of the remaining wild-type allele through mitotic recombination or chromosomal loss.

Key Tumor Suppressor Genes

TP53 — "Guardian of the Genome" — But What Does It Actually Do?

p53 (encoded by TP53) is a tetrameric transcription factor that functions as a stress-response hub. Rather than calling it merely a "guardian" without explanation, its specific, context-dependent roles are:

• DNA damage response: When ionizing radiation or genotoxic drugs cause double-strand breaks, kinases ATM and ATR phosphorylate p53, blocking its Mdm2-mediated degradation. p53 accumulates, tetramerizes, and binds DNA.
• Cell-cycle arrest: p53 transcribes CDKN1A (p21), which inhibits cyclin E–Cdk2 and cyclin A–Cdk2, freezing the cell in G₁ to allow time for DNA repair.
• DNA repair facilitation: p53 transcribes genes involved in nucleotide excision repair (XPC, DDB2) and directly interacts with repair proteins at damage sites.
• Senescence: Under chronic, low-level stress (e.g., oncogene activation), p53 can drive a permanent cell-cycle exit program distinct from apoptosis.
• Apoptosis: Under catastrophic damage, p53 transcribes pro-apoptotic BH3-only genes (PUMA, NOXA, BAX) and represses anti-apoptotic BCL2, committing the cell to intrinsic-pathway apoptosis.

TP53 is mutated in >50% of human cancers, with most mutations occurring in the DNA-binding domain, abolishing its transcriptional activity. Many are missense mutations that produce a stable but non-functional protein that can exert dominant-negative effects by poisoning tetramers containing wild-type subunits.

RB1 — The Retinoblastoma Protein

Rb governs the G₁→S transition (detailed in Topic 7-02). Loss of both RB1 alleles removes the primary brake on E2F-dependent transcription, rendering cells insensitive to growth-inhibitory signals. Germline RB1 mutations cause bilateral retinoblastoma in children; somatic RB1 loss occurs in many sporadic cancers, and the Rb pathway is functionally inactivated in virtually all human cancers — if not by RB1 mutation itself, then by CDK4 amplification, CCND1 (cyclin D) overexpression, or CDKN2A (p16) deletion.

APC — The Gatekeeper of Colorectal Cancer

The adenomatous polyposis coli (APC) protein is a scaffold that targets β-catenin for degradation in the Wnt signaling pathway. In unstimulated cells, APC partners with Axin, GSK-3β, and CK1 in the destruction complex, phosphorylating β-catenin and targeting it for ubiquitin-mediated proteolysis. Loss of APC → β-catenin stabilization → nuclear translocation → constitutive activation of TCF/LEF target genes (including MYC and CCND1). Germline APC mutations cause familial adenomatous polyposis (FAP), where hundreds of colonic polyps develop by early adulthood. Somatic APC mutations are the initiating event in >80% of sporadic colorectal cancers.

BRCA1 and BRCA2 — DNA Repair Factors, Not Just "Breast Cancer Genes"

BRCA1 and BRCA2 are tumor suppressor genes whose protein products are central to homologous recombination (HR), the high-fidelity pathway for repairing DNA double-strand breaks.

Molecular Functions

• BRCA1: A large scaffolding protein that is recruited to DNA damage sites in complex with BARD1. It promotes DNA end resection (generating 3′ single-stranded overhangs required for HR), recruits repair factors including BRCA2, and participates in the S/G₂ checkpoint through interactions with ATM/ATR and Chk2. BRCA1 also has HR-independent roles in transcriptional regulation and chromatin remodeling.
• BRCA2: Directly loads RAD51 recombinase onto resected single-stranded DNA, displacing RPA. RAD51 filaments then perform homology search and strand invasion — the core reactions of homologous recombination.

When BRCA1 or BRCA2 function is lost, cells cannot repair double-strand breaks by the error-free HR pathway and instead rely on non-homologous end joining (NHEJ) and other error-prone pathways, leading to chromosomal translocations, deletions, and genomic instability. This genome instability drives the accumulation of additional oncogenic mutations. Critically, BRCA-deficient tumors are exquisitely sensitive to PARP inhibitors — PARP is required for single-strand break repair, and when single-strand breaks persist into replication forks, they become double-strand breaks that BRCA-mutant cells cannot repair. This synthetic lethality is a paradigm for targeted cancer therapy.

The "breast cancer gene" label is a clinical shorthand — BRCA1/2 germline mutations confer a ~50–80% lifetime risk of breast cancer and ~20–40% lifetime risk of ovarian cancer, but also increase risk of pancreatic, prostate, and (for BRCA2) male breast cancer. The genes are ubiquitously expressed DNA repair factors; their association with breast and ovarian tissue reflects the particular sensitivity of those tissues to HR deficiency, possibly related to estrogen metabolism, tissue-specific transcriptional programs, or the proliferation rates of mammary and ovarian epithelium.

Questions

Q1: Why are oncogenic mutations typically dominant while tumor-suppressor mutations are recessive at the cellular level, and what exception exists?

A1: Oncogenes drive cancer through gain-of-function — a single mutant allele produces a hyperactive protein whose effect is not counteracted by the wild-type allele. Ras(G12V), for example, is locked in the GTP-bound active state regardless of what the normal Ras allele does. Tumor suppressors drive cancer through loss-of-function — the wild-type allele produces enough functional protein to maintain normal growth control. Both alleles must be inactivated ("two hits"). The exception is haploinsufficiency: for some tumor suppressors (e.g., TP53, PTEN), loss of a single allele reduces protein dosage below the threshold needed for full tumor suppression, accelerating tumorigenesis even before the second allele is lost. Additionally, some TP53* missense mutations produce dominant-negative proteins that poison wild-type p53 tetramers, effectively inactivating p53 with just one mutant allele.*

Q2: Explain how APC loss connects Wnt signaling, β-catenin, and stem-cell dynamics in the colonic crypt.

A2: In normal colonic crypts, Wnt ligands from stromal cells at the crypt base maintain a gradient of nuclear β-catenin that drives stem-cell proliferation. As cells migrate up the crypt, Wnt signaling diminishes, APC-mediated β-catenin degradation increases, and cells differentiate and eventually undergo apoptosis at the luminal surface. APC loss short-circuits this spatial control: β-catenin accumulates in the nucleus regardless of position, TCF/LEF target genes (including MYC) are constitutively active, and cells retain a stem-like proliferative state instead of differentiating. The result is a crypt filled with undifferentiated, proliferating cells — a microadenoma. This is why APC* is the gatekeeper — it controls the switch between the proliferative crypt base and the differentiated crypt top, and its loss is the rate-limiting first step in colorectal tumorigenesis.*

Q3: Why does loss of BRCA1/2 preferentially predispose to breast and ovarian cancer rather than causing cancer in all tissues equally?

A3: This tissue specificity is incompletely understood but likely multifactorial: (1) Estrogen metabolites can generate oxidative DNA damage in breast and ovarian epithelium, increasing the burden of double-strand breaks that HR must repair. (2) BRCA1 has tissue-specific transcriptional co-regulatory roles in mammary epithelium, including estrogen receptor signaling, that are independent of its DNA repair function. (3) The high proliferative rate of mammary and ovarian epithelium during reproductive cycles creates replication stress and replication-associated DNA damage that requires HR. (4) Tissue-specific compensatory pathways — some tissues may upregulate alternative repair pathways when HR is lost, while breast epithelium may be less capable of compensation. Notably, PARP inhibitors exploit HR deficiency in any tissue, and BRCA-mutant pancreatic and prostate cancers respond to PARP inhibitors, confirming that the DNA repair defect is universal even if tumorigenesis is tissue-biased.